Adalimumab therapy of noninfectious uveitis Review article

Article Sidebar

PDF (Język Polski)


Published: Jun 30, 2020
DOI: https://doi.org/10.24292/01.OT.300620.1
Keywords:
biological therapy, non-infectious uveitis, TNF-α inhibitors, adalimumab

Main Article Content

Julia Kręcicka
Uniwersytecki Szpital Kliniczny we Wrocławiu
http://orcid.org/0000-0003-3895-3096
Anna Turno-Kręcicka
Katedra i Klinika Okulistyki Uniwersytetu Medycznego we Wrocławiu
http://orcid.org/0000-0001-6732-1851
Marta Misiuk-Hojło
Katedra i Klinika Okulistyki Uniwersytetu Medycznego we Wrocławiu
http://orcid.org/0000-0002-4020-3203

Abstract

Noninfectious uveitis is known for its chronic and cumulative nature. It is often associated with diagnostic and therapeutic difficulties. It causes significant vision loss in young patients, making them incapable of maintaining an active work life. Diagnosis and treatment require cooperation between different specialists and are based on multiple blood tests and other diagnostic tests. This article presents medical indications and the safety and efficacy of adalimumab, a tumor necrosis factor inhibitor and the first biological drug used in ophthalmology. Adalimumab is an important therapeutic option for the treatment of intermediate, posterior, and pan-uveitis, enabling patients to obtain and maintain long-term disease control during simultaneous corticosteroid/immunomodulatory therapy or without it.

Downloads

Download data is not yet available.

Article Details

How to Cite
1.
Kręcicka J, Turno-Kręcicka A, Misiuk-Hojło M. Adalimumab therapy of noninfectious uveitis. Ophthatherapy [Internet]. 2020Jun.30 [cited 2024Nov.22];7(2):90-5. Available from: https://journalsmededu.pl/index.php/ophthatherapy/article/view/1035
Issue
Vol 7 No 2 (2020)
Section
Conservative treatment
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Copyright: © Medical Education sp. z o.o. License allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)

References

1. LaMattina KC, Goldstein DA. Adalimumab for the treatment of uveitis, Expert Rev Clin Immunol. 2017; 13(3): 181-8.
2. Sippy BD, Hofman FM, Wright AD et al. Soluble tumor necrosis factor receptors are present in human vitreous and shed by retinal pigment epithelial cells. Exp Eye Res. 1996; 63(3): 311-7.
3. Jaffe GJ, Dick AD, Brézin AP et al. Adalimumab in patients with active noninfectious uveitis. N Engl J Med. 2016; 375(10): 932-43.
4. Rudwaleit M, Rodevand E, Holck P et al. Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann Rheum Dis. 2009; 68(5): 696-701.
5. Van Denderen JC, Visman IM, Nurmohamed MT et al. Adalimumab significantly reduces the recurrence rate of anterior uveitis in patients with ankylosing spondylitis. J Rheumatol. 2014; 41(9): 1843-8.
6. Kim M, Won JY, Choi SY et al. Anti-TNF-α Treatment for HLA-B27-Positive Ankylosing Spondylitis-Related Uveitis. Am J Ophthal. 2016; 170: 32-40.
7. Bawazeer A, Raffa LH, Nizamuddin SH. Clinical experience with adalimumab in the treatment of ocular Behçet disease. Ocul Immunol Inflamm. 2010; 18(3): 226-32.
8. Fabiani C, Vitale A, Emmi G et al. Efficacy and safety of adalimumab in Behçet’s disease-related uveitis: a multicenter retrospective observational study. Clin Rheumatol. 2017; 36(1): 183-9.
9. Steeples LR, Spry P, Lee RWJ et al. Adalimumab in refractory cystoid macular edema associated with birdshot chorioretinopathy. International Ophthalmology. 2018; 38(3): 1357-62.
10. Hiyama T, Harada Y, Kiuchi Y. Effective treatment of refractory sympathetic ophthalmia with glaucoma using adalimumab. Am J Ophthalmol Case Rep. 2019; 14: 1-4.
11. Erckens RJ, Mostard RL, Wijnen PA et al. Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis. Graefes Arch Clin Exp Ophthalmol. 2012; 250(5): 713-20.
12. Castiblanco C, Meese H, Foster CS. Treatment of pediatric uveitis with adalimumab: the MERSI experience. J Aapos. 2016; 20(2): 145-7.
13. Nguyen QD, Merrill PT, Jaffe GJ et al. Adalimumab for prevention of uveitic flare in patients with active non-infectious uveitis controlled by cortiocosteroids (VISUAL II): a multicenter, double-masked, randomized, placebo-controlled phase 3 trial. Lancet. 2016; 388: 1183-92.
14. Suhler EB, Adán A, Brézin AP et al. Safety and efficacy of adalimumab in patients with noninfectious uveitis in an ongoing open-label study: VISUAL III. Ophthalmology. 2018; 125: 1075-87.
15. Vallet H, Seve P, Biard L et al. Infliximab versus adalimumab in the treatment of refractory inflammatory uveitis: a multicenter study from the French uveitis network. Arthritis Rheumatol. 2016; 68: 1522-30.
16. Fabiani C, Vitale A, Rigante D et al. Comparative efficacy between adalimumab and infliximab in the treatment of non-infectious intermediate uveitis, posterior uveitis, and panuveitis: a retrospective observational study of 107 patients. Clin Rheumatol. 2019; 38: 407-15.
17. Rosenbaum JT, Bodaghi B, Couto C et al. New observations and emerging ideas in diagnosis and management of non-infectious uveitis: A review. Semin Arthritis Rheum. 2019; 49(3): 438-45.
18. Załącznik B.105. Leczenie zapalenia błony naczyniowej oka (ZBN) – część pośrednia, odcinek tylny lub cała błona naczyniowa (ICD-10 H 20.0, H 30.0). https://www.nfz.gov.pl.